<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057889</url>
  </required_header>
  <id_info>
    <org_study_id>030094</org_study_id>
    <secondary_id>03-C-0094</secondary_id>
    <secondary_id>CDR0000285624</secondary_id>
    <nct_id>NCT00057889</nct_id>
    <nct_alias>NCT00053729</nct_alias>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer</brief_title>
  <official_title>A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients who have metastatic renal cell cancer (kidney cancer) that is refractory to&#xD;
      treatment with interleukin-2 or unable to be treated with interleukin-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the activity of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal&#xD;
           antibody in patients with metastatic clear cell renal cancer who are refractory to or&#xD;
           ineligible for interleukin-2.&#xD;
&#xD;
        -  Determine the impact of this drug on T-cell number and phenotype in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over&#xD;
      90 minutes once every 3 weeks for up to 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with an ongoing partial response may receive additional&#xD;
      courses of therapy.&#xD;
&#xD;
      Patients are followed at 4 weeks, every 3 months for 1 year, every 6 months for 2 years, and&#xD;
      then annually until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-103 patients will be accrued for this study within 2-4&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IV clear cell renal carcinoma&#xD;
&#xD;
          -  At least 1 site of measurable disease&#xD;
&#xD;
          -  Meeting criteria for 1 of the following:&#xD;
&#xD;
               -  Disease progression after prior interleukin-2 (IL-2)&#xD;
&#xD;
               -  Ineligible for standard high-dose IV IL-2 due to comorbid medical conditions&#xD;
&#xD;
               -  Minimal disease (lesions ≤ 3 cm that do not pose risk to organ function) such&#xD;
                  that participation in this study is not likely to compromise the patient's&#xD;
                  opportunity to receive future high-dose IL-2&#xD;
&#xD;
               -  Indolent disease (defined as an increase in tumor size of &lt; 50% within the past 6&#xD;
                  months) such that participation in this study is not likely to compromise the&#xD;
                  patient's opportunity to receive future high-dose IL-2&#xD;
&#xD;
               -  No true papillary, medullary, chromophobe, collecting duct, or oncocytic renal&#xD;
                  cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 2,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Hematocrit ≥ 30%&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ ULN (&lt; 3.0 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy except adequately treated basal cell or squamous cell skin cancer,&#xD;
             superficial bladder cancer, or carcinoma in situ of the cervix or any other cancer&#xD;
             from which the patient has been disease free for at least 5 years&#xD;
&#xD;
          -  No autoimmune disease (including uveitis and autoimmune inflammatory eye disease)&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy for renal cancer&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy for renal cancer&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 3 weeks since prior hormonal therapy for renal cancer&#xD;
&#xD;
          -  More than 4 weeks since prior corticosteroids&#xD;
&#xD;
          -  No concurrent systemic or topical corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy for renal cancer&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 3 weeks since other prior therapy for renal cancer&#xD;
&#xD;
          -  No concurrent immunosuppressive agents (e.g., cyclosporine and its analog)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

